Detalhe da pesquisa
1.
The Development of STING Agonists and Emerging Results as a Cancer Immunotherapy.
Curr Oncol Rep
; 25(3): 189-199, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36705879
2.
Targeted Toxicities: Protocols for Monitoring the Adverse Events of Targeted Therapies Used in the Treatment of Non-Small Cell Lung Cancer.
Int J Mol Sci
; 24(11)2023 May 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-37298380
3.
Evaluation of Major Pathologic Response and Pathologic Complete Response as Surrogate End Points for Survival in Randomized Controlled Trials of Neoadjuvant Immune Checkpoint Blockade in Resectable in NSCLC.
J Thorac Oncol
; 2024 Mar 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38461929
4.
What is the ideal endpoint in early-stage immunotherapy neoadjuvant trials in lung cancer?
Ther Adv Med Oncol
; 15: 17588359231198446, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37720499